Stefan Harsanyi - Genetic Mutations

Author Information

Stefan Harsanyi is affiliated with the Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University in Bratislava, Slovakia. He has contributed significantly to the field of genetics, particularly in relation to Developmental Dysplasia of the Hip (DDH) and oncology.

Research Contributions

Stefan Harsanyi's research primarily revolves around the genetic aspects of Developmental Dysplasia of the Hip (DDH) and various cancer biomarkers. He has extensively studied the associations between specific genes such as GDF5, IL6, and PAPPA2 with DDH in infants. His work also includes the prognostic and diagnostic value of biomarkers like E-cadherin, Ki-67, and p53 in bladder cancer. His research has provided insights into the genetic screening for DDH and the identification of prognostic biomarkers in osteosarcoma and transitional cell carcinoma of the bladder.

Aliases

S Harsanyi, Š Harsányi, Stefan Harsanyi

Publication and Citation Metrics

Metric	Value
Citation Count	186
h-index	8
Paper Count	18

Publications:

Association Analysis of GDF5 and Contributing Factors in Developmental Dysplasia of the Hip in Infants.

DOI: 10.5604/01.3001.0015.4348

Year: 2021

Genetic Study of IL6, GDF5 and PAPPA2 in Association with Developmental Dysplasia of the Hip

DOI: 10.3390/genes12070986

Year: 2021

The prognostic value of E-cadherin and Ki-67 compared to standard histopathologic examination in non-muscle invasive bladder cancer.

DOI: 10.4149/bll_2020_072

Year: 2020

Genetics of developmental dysplasia of the hip.

DOI: 10.1016/j.ejmg.2020.103990

Year: 2020

Developmental Dysplasia of the Hip: A Review of Etiopathogenesis, Risk Factors, and Genetic Aspects

DOI: 10.3390/medicina56040153

Year: 2020

Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence

DOI: 10.4081/ejh.2020.3098

Year: 2020

Developmental Dysplasia of Hip: Perspectives in Genetic Screening

DOI: 10.3390/medsci7040059

Year: 2019

Identification of Prognostic and Predictive Osteosarcoma Biomarkers

DOI: 10.3390/medsci7020028

Year: 2019

Expression of FOXA1 and GATA3 correlates with invasivity and pathological stage a grade of primary transitional cell carcinoma of the bladder

DOI: 10.1096/fasebj.2019.33.1_supplement.lb370

Year: 2019

Can Genetic Mutations be Prevented or Repaired?

How do Genetic Mutations Affect Health?

What Are the Implications for Treatment and Management?

What are Autism Spectrum Disorders?

What is Gene Amplification?

What is Pharmacogenomics?

What Are Some Common Types of Genetic Diseases?

How Do Mutations Contribute to Evolution?

How is Biotechnology Applied in Medicine?

How is Karyotyping Performed?

Partnered Content Networks

Relevant Topics